Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile Results support DNTH103’s best-in-class potential to be the first subcutaneous, self-administered injection dosed as
The combined company will operate as “Dianthus Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “DNTH” effective Tuesday, September 12, 2023 CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) today announced
Experienced life sciences executive brings more than a decade of public company expertise in legal, corporate governance and compliance New York City and Waltham, Mass., June 20, 2023 – Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million
Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H’23 DNTH103 is a next-generation monoclonal antibody that selectively targets only the active form of the C1s protein in the classical complement
Lead program DNTH103 to be accelerated to the clinic this year as a highly differentiated and potent monoclonal antibody designed to selectively target the active form of complement C1s Led by biotech veterans Marino Garcia as Chief Executive Officer and Lonnie Moulder as Chairman of the Board
